Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GlaxoSmithKline : Data show anti-tumour activity with ICOS agonist

share with twitter share with LinkedIn share with facebook
share via e-mail
09/30/2019 | 02:09am EST

Issued: 28 September 2019, London UK

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function,showed promising anti-tumour activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcinoma (HNSCC). Findings from the INDUCE-1 study also suggested GSK3359609 has single agent activity in patients with PD-1/L1 experienced HNSCC.

The safety and tolerability profile of GSK3359609was consistent with the results reported in the dose escalation phase of INDUCE-1.The data were presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.

Dr. Axel Hoos, Senior Vice President and Head Oncology R&D, said: 'Immunotherapies such as GSK3359609are a critical part of our oncology pipeline and we are encouraged by the INDUCE-1 data demonstrating the potential of this agent to enhance anti-tumour activity beyond what PD-1 blockade alone has demonstrated. The clinical responses observed are encouraging and, based on precedent with CTLA-4 or PD-1, we aim to demonstrate the main effect of our ICOS agonist to be on improving survival for patients, which requires further study. Based on these results, we are initiating the INDUCE-3 registrational trial to investigate the potential survival benefit of GSK3359609 with pembrolizumab in first-line recurrent/metastatic HNSCC for patients who are PD-L1 positive.'

The data presented stem from the expansion phase of INDUCE-1, a first-in-human, open-label study investigating GSK3359609 as a monotherapy and in combination with other regimens. Patients in the study had recurrent or metastatic HNSCC and had received up to five prior lines of therapy in the advanced setting. Patients in the monotherapy cohort had previously been treated with PD-1/L1 therapy and received 1 mg/kg GSK3359609. Patients in the combination cohort were naive to PD-1/L1 therapy and received 0.3 mg/kg GSK3359609 and 200 mg pembrolizumab. Patients in both cohorts were evaluated until disease progression or unacceptable toxicity, for up to two years.

In the 34 evaluable patients who received the combination therapy, the overall response rate was 24% (n=8; 95% CI: 11, 58.7). Responses in the combination cohort were durable with all responding patients maintaining benefit for 6 months or longer (median not reached; 95% CI: 4.2 months, NR); the median progression-free survival (PFS) was 5.6 months (95% CI: 2.4, 7.4). Of the 21 patients with known PD-L1 expression data, the majority of responders and patients with stable disease had PD-L1 score below 20. Of the 16 evaluable patients who received monotherapy, the overall response rate was 6% (n=1; 95% CI: 0.2, 30.2).

The INDUCE-1 study was conducted pursuant to an agreement between GSK and Merck & Co, Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the U.S. and Canada). GSK is continuing its relationship with MSD to support the INDUCE-3 phase II/III combination trial to be initiated by the end of 2019.

HNSCC is a cancer that develops from squamous cells in the mucous membranes of the mouth, nose and throat, and is the seventh most common cancer worldwide with approximately 600,000 new cases diagnosed each year.[i]Although HNSCC occurs more frequently in men in their 50s or 60s, the incidence is increasing among younger individuals.[ii]HNSCC tumours are highly immunogenic and have an elevated expression of immune checkpoint modulators, including ICOS and PD-1.[iii]

GSK3359609 Clinical Development Programme

The clinical development programme for GSK3359609 looks to investigate the anti-tumour potential of targeting the ICOS receptor through an agonist antibody alone and in combination with other immune checkpoint therapies for the treatment of a range of tumour types.

GSK3359609 is not currently approved for use anywhere in the world.

GSK in Oncology

GSK is focused on maximising patient survival through transformational medicines. GSK's pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information, please visit www.gsk.com.

GSK enquiries:

UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502


Tim Foley

+44 (0) 20 8047 5502


US Media enquiries:

Kristen Neese

+1 (804) 217-8147


Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194


Danielle Smith

+44 (0) 20 8047 2406


James Dodwell

+44 (0) 20 8047 2406


Jeff McLaughlin

+1 215 751 7002


Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex



GSK - GlaxoSmithKline plc published this content on 30 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2019 06:07:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
11/11ANDREW WITTY : UnitedHealth Group Names Andrew Witty as President
11/07GLAXOSMITHKLINE : EACS 2019 ViiV Healthcare to present 17 abstracts from its por..
10/31UK's winter election - What's in it for markets?
10/30LONDON STOCK EXCHANGE : Pharma stocks lift FTSE 100 out of red
10/30GLOBAL MARKETS LIVE : PSA, Fiat Chrysler, Macquarie, WhatsApp…
10/30GSK raises profit forecast after shingles vaccine sales boost
10/30GLAXOSMITHKLINE : Intravenous Benlysta is the first biologic treatment to be app..
10/30GlaxoSmithKline Raises Guidance After 3Q Profit Rise -- Update
10/30GLAXOSMITHKLINE : 3rd Quarter Results
10/30GLAXOSMITHKLINE : Raises Outlook as 3Q Revenue, Profit Grow
More news
Financials (GBP)
Sales 2019 33 385 M
EBIT 2019 9 007 M
Net income 2019 4 388 M
Debt 2019 24 564 M
Yield 2019 4,60%
P/E ratio 2019 19,1x
P/E ratio 2020 16,0x
EV / Sales2019 3,31x
EV / Sales2020 3,08x
Capitalization 86 084 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 805,27  GBp
Last Close Price 1 739,40  GBp
Spread / Highest target 26,5%
Spread / Average Target 3,79%
Spread / Lowest Target -13,2%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.27%344 670
ROCHE HOLDING AG22.47%254 722
MERCK AND COMPANY10.09%211 953
PFIZER-15.30%208 023
NOVARTIS19.53%198 320